Tiantai Yinkang Biomedical

Yinkang Biomedical is a clinical-stage biotechnology company based in China, specializing in the development of innovative small molecule therapeutics for cancer treatment. The company's primary focus is on precision oncology, with a lead candidate, YK-029, which is a third-generation EGFR tyrosine kinase inhibitor targeting non-small cell lung cancer. Yinkang Biomedical operates research and development facilities in Hangzhou and manufacturing sites in Tiantai, Zhejiang. The firm aims to provide high-quality, affordable targeted therapies to patients with unmet medical needs in the oncology space. Its pipeline includes several other small molecule candidates in various stages of preclinical and clinical development.